Life Sciences Recovery Roadmap

The COVID-19 crisis has powerfully demonstrated the strategic importance of the life science sector to the UK’s health, security, and to the economy.

The Life Sciences industry and charities have played a central role in tackling the COVID-19 pandemic.  By creating new partnerships with the Government and NHS the sector has rapidly scaled up UK diagnostic capacity; supported the NHS to deliver care in a period of exceptional patient demand; and are leading the search for vaccinations and treatments to tackle the pandemic.

We have also seen the future of healthcare in action.  The scientific and technological revolution of the Life Sciences sector – from the use of AI and machine learning in R&D to the latest manufacturing technologies and new treatment paradigms – bringing real value to solving health challenges through new therapies and vaccines.

The Life Sciences Recovery Roadmap sets out how the sector can work with the Government and the NHS so that the sector is at the heart of the economic recovery and can support the NHS in getting cutting edge healthcare to patients.

This paper was submitted to Government by trade bodies that represent the life sciences and charity research sectors through the Life sciences COVID-19 Response Group, co-Chaired by Lord Bethell and Nadhim Zahawi MP.

The Roadmap provides an overview of the critical issues affecting the sector as we look towards recovery and building a new partnership between the Life sciences sector, Government and NHS. 

 

The report focuses on six critical areas:

  • Transforming our partnership with the NHS to support delivery of the Long-Term Plan.
  • Developing a comprehensive strategy to improve UK manufacturing capability and supply chain resilience in medicines, medical devices and diagnostics.
  • Powering up the benefits of public and charity spending on medical research and delivering bold policies to incentivise research investment.
  • Transforming the UK’s clinical research processes.
  • Taking an innovative approach to regulation:
  • Accelerating deployment of new and existing treatments and technologies where there are system and patient benefits.

More within